| name | es-cgm-vs-none-t2d-insu-su-high-risk |
| description | This skill suggests using real-time continuous glucose monitoring (CGM) rather than no CGM for outpatients with type 2 diabetes (T2D) who take insulin and/or sulfonylureas and are at high risk for hypoglycemia. It is triggered by clinician questions such as "Should I use CGM for this T2D patient on insulin or sulfonylureas with high hypoglycemia risk?" or "Is CGM indicated for this patient?" |
CGM vs No CGM for T2D on Insulin/SU at High Risk
STEP 1 — Gather Information
Collect patient demographics, confirm type 2 diabetes outpatient status, list current medications (focus on insulin and/or sulfonylureas), and document hypoglycemia history (severe episodes requiring assistance, impaired awareness of hypoglycemia, renal/hepatic dysfunction, age-related risk).
STEP 2 — Rule In / Rule Out
Determine if the patient is an outpatient with T2D prescribed insulin and/or a sulfonylurea. If yes, proceed to assess hypoglycemia risk; if no, CGM is not indicated per this recommendation (stop).
STEP 3 — Classify or Stratify
Assess for high hypoglycemia risk: history of severe hypoglycemia requiring assistance, impaired awareness of hypoglycemia (IAH), or medical conditions predisposing to severe hypoglycemia (renal/hepatic dysfunction, older age). If high risk, proceed; if not high risk, CGM is not suggested per this guideline (though consider other indications).
STEP 4 — Decide
For patients meeting criteria (T2D outpatient on insulin/SU and high hypoglycemia risk), suggest initiating real-time CGM rather than no CGM, combined with periodic point-of-care blood glucose (POC-BG) testing to validate CGM accuracy.
Clinical Guardrails / Mimics / Pitfalls
CGM does not replace SMBG; fingerstick glucose remains necessary for calibration, confirmation of discordant symptoms, and sensor warm-up periods. Ensure patient receives education on device use, troubleshooting, interpreting trend arrows, and responding to alerts. Be mindful of cost, insurance coverage, and patient acceptability; avoid using CGM alone for acute treatment decisions without confirmatory SMBG. Note that inpatient CGM use lacks FDA approval but may be used under enforcement discretion; assess patient ability to handle device alerts and data burden.
Concrete Clinical Example
A 68‑year‑old man with T2D on basal insulin glargine and glimepiride (a sulfonylurea) reports recurrent hypoglycemia unawareness and two severe hypoglycemic events requiring assistance in the past month. He is an outpatient on insulin/SU and at high risk. The skill suggests initiating real‑time CGM with diabetes education and periodic SMBG validation.
Source: Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac596
